Predicting Rheumatoid Arthritis Treatment Success New Biomarker Breakthrough Key Takeaways Rheumatoid arthritis is a chronic systemic autoimmune disease affecting approximately 1 percent of the global population. Despite major advances in biologic and targeted synthetic disease modifying antirheumatic drugs, treatment success remains highly variable. Approximately
Family Practice Medicine
Food Allergy Desensitization: Is Oral Immunotherapy Ready for Prime Time?
Food Allergy Desensitization: Is Oral Immunotherapy Ready for Prime Time? Abstract Food allergies affect millions of people worldwide and can cause severe, life-threatening reactions. Traditional management has focused on strict food avoidance and emergency treatment. Oral immunotherapy (OIT) has emerged as a promising treatment
Prediabetes Management in Family Practice: Comparative Effectiveness of Lifestyle Intervention, Metformin, and Anti-Obesity Pharmacotherapy
Prediabetes Management in Family Practice Comparative Effectiveness of Lifestyle Intervention, Metformin, and Anti-Obesity Pharmacotherapy Abstract Prediabetes represents a critical window for intervention in the trajectory toward type 2 diabetes mellitus, offering family physicians an opportunity to prevent or significantly delay disease onset. With global
Beyond Thresholds: Why Continuous Risk Assessment Improves Hypertension Treatment
Beyond Thresholds: Why Continuous Risk Assessment Improves Hypertension Treatment Introduction Hypertension treatment based solely on blood pressure thresholds may miss critical opportunities to prevent cardiovascular disease. For decades, physicians have relied on the 140/90 mm Hg cutoff to determine which patients require pharmacological
Are We Overtreating Early Rheumatoid Arthritis in the Biologic Era?
Are We Overtreating Early Rheumatoid Arthritis in the Biologic Era Abstract The introduction of biologic disease modifying antirheumatic drugs has fundamentally reshaped the management of rheumatoid arthritis over the past two decades. These agents, in combination with conventional synthetic therapies and treat to target strategies, have significantly
Biological vs Chronological Age: Are Geriatricians Ready for ‘Aging Clocks’?
Biological vs Chronological Age: Are Geriatricians Ready for ‘Aging Clocks’? Abstract The concept of biological age versus chronological age represents a fundamental shift in how healthcare providers assess aging and age-related health risks. While chronological age measures the time elapsed since birth, biological
Metformin in 2025: Still the King or Time to Step Aside?
Anemia of Chronic Disease: Unravelling New Pathways Beyond Iron
Anemia of Chronic Disease: Unravelling New Pathways Beyond Iron Abstract Anemia of chronic disease (ACD) represents the second most common form of anemia worldwide, affecting millions of patients with underlying inflammatory conditions. Traditionally understood as a disorder primarily involving disruption of iron metabolism, recent
Hidden Crisis: Why Sarcopenia Treatment Matters More Than You Think in 2025
Hidden Crisis: Why Sarcopenia Treatment Matters More Than You Think in 2025 Introduction Sarcopenia treatment represents a critical healthcare priority as the prevalence of this age-related muscle wasting condition reaches alarming levels. The economic burden of sarcopenia in the United States was approximately
The Tirzepatide Revolution: Is Dual Agonism the End of Single-Pathway Therapy?
The Tirzepatide Revolution: Is Dual Agonism the End of Single-Pathway Therapy? Abstract The development of tirzepatide, a first in class dual glucose dependent insulinotropic polypeptide and glucagon like peptide 1 receptor agonist, represents a potentially transformative advance in the management of type 2 diabetes and obesity. By simultaneously targeting
